ACE inhibitors in non-ischaemic heart failure: Results from the MEGA trials

Keyphrases

• Ischemic Heart Failure 100%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 100%
• Vasodilator 33%
• Long-term Benefit 33%
• Inhibitor Therapy 33%
• Chronic Heart Failure 33%
• Heart Disease 33%
• Clinical Response 33%
• Physiological Mechanism 33%
• Pump Function 33%
• Neurohormonal 33%
• Inhibiting Effect 33%
• Ischemic Heart Disease 33%
• Non-ischemic 33%
• Optimal Dose 33%
• Ventricular Remodeling 33%
• Pharmacological Mechanism 33%
• Mortality Reduction 33%
• Antiarrhythmic Effect 33%
• Cardiovascular Event Rates 33%
• Growth Hindering 33%
• Ischemic Events 33%
• Large-scale Trials 33%

Medicine and Dentistry

• Heart Muscle Ischemia 100%
• Congestive Heart Failure 100%
• ACE Inhibitor 100%
• Ischemic Heart Disease 33%
• Heart Disease 33%
• Heart Ventricle Remodeling 33%
• Growth Inhibition 33%
• Optimal Drug Dose 33%
• Antiarrhythmic Activity 33%
• Cardiovascular System 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Heart Muscle Ischemia 100%
• Dipeptidyl Carboxypeptidase Inhibitor 100%
• Congestive Heart Failure 100%
• Antiarrhythmic Drug 33%
• Heart Disease 33%
• Heart Ventricle Remodeling 33%
• Ischemic Heart Disease 33%